The Lyon Immunotherapy for Cancer Laboratory – LICL

The Lyon Immunotherapy for Cancer Laboratory (LICL) supports projects aiming to understand immune responses to cancer therapies.
More than a platform, we provide strategic and scientific expertise across all stages — from data generation and analysis to interpretation and valorization —  for cohort analyses, clinical trial immune monitoring, resistance mechanisms and target discovery, Preclinical evaluation of identified targets and drugs.
We also lead/assist partners in securing competitive funding.

For any project request : licl@lyon.unicancer.fr

Latest news

LICL main publications

Integration of expertises : scientific insights and clinical outcome

Our expertises converge toward the identification of predictive biomarkers of response and resistance mechanisms to propose alternative therapeutic strategies.

SPOTLIGHT
By integrating RNA-seq and multiplex immunofluorescence on paired samples from the NeoPembrOv phase II trial, our work revealed key determinants of response to neoadjuvant chemotherapy plus pembrolizumab in high-grade ovarian carcinoma.

• Combination therapy increased intraepithelial CD8⁺PD-1⁺ T cells
• A composite endothelial-monocyte-T cell signature predicted response with AUC = 0.93
• High CD8B/FOXP3 and CD8B/ENTPD1 ratios correlated with response, while VEGFR2 expression marked resistance

These findings highlight regulatory T cells and VEGFR2⁺ endothelial cells as potential targets to overcome immune resistance in ovarian cancer.

https://www.nature.com/articles/s41467-024-47000-5
Le Saux et al., Nature Communications (2024) 

They trust us

Governance and operational structure

The LICL Team